Publications by authors named "E Blair Holladay"
Real-World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy.
Arthritis Care Res (Hoboken)
October 2024
Objective: The objective of this study was to ascertain pegloticase persistence and adverse events associated with concomitant immunomodulatory drug treatment in patients with gout.
Methods: We conducted a retrospective analysis of patients with gout using the American College of Rheumatology's Rheumatology Informatics System for Effectiveness registry from January 2016 through June 2020. The first pegloticase infusion defined the index date.
Background/purpose: Little is known about long-term clinical outcomes or urate-lowering (ULT) therapy use following pegloticase discontinuation. We examined ULT use, serum urate (SU), inflammatory biomarkers, and renal function following pegloticase discontinuation.
Methods: We conducted a retrospective analysis of gout patients who discontinued pegloticase using the Rheumatology Informatics System for Effectiveness (RISE) registry from 1/2016 to 6/2022.
COVID-19 Vaccine Uptake, Hesitancy, and Flare in a Large Rheumatology Practice Network.
Arthritis Care Res (Hoboken)
January 2024
Article Synopsis
- The study aimed to evaluate COVID-19 vaccine uptake, reasons for hesitancy, and self-reported disease flare in a large network of rheumatology practices.
- Out of 61,158 patients surveyed, 89% had received at least one vaccine dose, but those with autoimmune and inflammatory rheumatic diseases (AIIRDs) were less likely to be vaccinated and more hesitant compared to those without AIIRDs.
- Main reasons for hesitancy included safety concerns and side effects, while a lack of physician recommendation was a key factor for booster hesitancy; however, having AIIRD did not lead to higher rates of self-reported disease flare after vaccination.
Background: National efforts to control US healthcare spending are potentially undermined by changes in patient characteristics, and in particular increases in rates of obesity and overweight. The objective of this study was to provide current estimates of the effect of obesity and overweight on healthcare spending overall, by service line and by payer using the National Institutes of Health classifications for BMI.
Methods: We used a quasi-experimental design and analyzed the data using generalized linear models and two-part models to estimate obesity- and overweight-attributable spending.